Publications

Authors:

Zambonin, Valentina; De Toma, Alessandro; Carbognin, Luisa; Nortilli, Rolando; Fiorio, Elena; Parolin, Veronica; Pilotto, Sara; Cuppone, Federica; Pellini, Francesca; Lombardi, Davide; Pollini, Giovanni Paolo; Tortora, Giampaolo; Bria, Emilio

Title:

Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research

Year:

2017

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

EXPERT OPINION ON BIOLOGICAL THERAPY

ISSN of journal:

1471-2598

N° Volume:

17

Number or Folder:

4

:

Ashley Publications Limited:Unitec House, Third Floor, 2 Albert Place, Finchley Central, London N3 1QB United Kingdom:011 44 208 3433883, EMAIL: jdrake@ashley-pub.com, INTERNET: http://www.ashley-pub.com, Fax: 011 44 208 3432313

Page numbers:

497-506

Keyword:

Angiogenesis; bevacizumab; breast cancer; clinical trials; review; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomedical Research; Breast Neoplasms; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Neovascularization, Pathologic; Pragmatic Clinical Trials as Topic; Randomized Controlled Trials as Topic

Short description of contents:

Angiogenesis plays a fundamental role in breast cancer (BC) growth, progression and metastatic spread. After the promising introduction of bevacizumab for the treatment of advanced BC, the initial enthusiasm decreased when the FDA withdrew its approval in 2011. Nevertheless, several clinical studies exploring the role of bevacizumab have been subsequently published. Areas covered: The aim of this study is to review the available clinical trials exploring the potential effectiveness of bevacizumab in BC, regardless of the disease setting. Expert opinion: Even if the evidence suggests that bevacizumab must be ruled out from the HER2-positive and adjuvant setting, bevacizumab's benefit remains uncertain in the neoadjuvant setting and in the advanced treatment of HER2-negative patients. In the first setting, the addition of bevacizumab to chemotherapy increased the pathological complete response (pCR) rate in most clinical trials. However, the current absence of evidence that pCR is a trial-level surrogate for survival requires waiting for long-term results. In the advanced setting, all trials showed a benefit in progression-free survival, but not in overall survival, highlighting an increase of adverse events. The lack of predictors of response represents the main unmet need in which future clinical research will undoubtedly invest.

Product ID:

101170

Handle IRIS:

11562/974604

Last Modified:

November 15, 2022

Bibliographic citation:

Zambonin, Valentina; De Toma, Alessandro; Carbognin, Luisa; Nortilli, Rolando; Fiorio, Elena; Parolin, Veronica; Pilotto, Sara; Cuppone, Federica; Pellini, Francesca; Lombardi, Davide; Pollini, Giovanni Paolo; Tortora, Giampaolo; Bria, Emilio, Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research «EXPERT OPINION ON BIOLOGICAL THERAPY» , vol. 17 , n. 4 , 2017 , pp. 497-506

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo